Exencial Wealth Advisors LLC Sells 4,137 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Exencial Wealth Advisors LLC reduced its stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 2.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 184,794 shares of the company’s stock after selling 4,137 shares during the period. Exencial Wealth Advisors LLC’s holdings in GE HealthCare Technologies were worth $14,447,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Mesirow Financial Investment Management Inc. boosted its holdings in GE HealthCare Technologies by 39.6% during the third quarter. Mesirow Financial Investment Management Inc. now owns 4,084 shares of the company’s stock worth $383,000 after purchasing an additional 1,159 shares during the last quarter. Cathy Pareto & Associates Inc. bought a new position in shares of GE HealthCare Technologies during the 4th quarter worth approximately $670,000. LMR Partners LLP purchased a new position in shares of GE HealthCare Technologies in the 3rd quarter worth approximately $7,387,000. Principal Financial Group Inc. grew its holdings in shares of GE HealthCare Technologies by 1.9% in the third quarter. Principal Financial Group Inc. now owns 1,009,910 shares of the company’s stock valued at $94,780,000 after acquiring an additional 19,010 shares in the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in shares of GE HealthCare Technologies during the third quarter valued at approximately $1,396,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on GEHC shares. Wells Fargo & Company boosted their price objective on GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Jefferies Financial Group raised shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and boosted their price target for the stock from $95.00 to $103.00 in a report on Wednesday, January 8th. Finally, Citigroup raised their price objective on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, GE HealthCare Technologies currently has an average rating of “Moderate Buy” and a consensus target price of $97.67.

GE HealthCare Technologies Stock Performance

NASDAQ GEHC opened at $86.45 on Tuesday. The firm has a market cap of $39.53 billion, a P/E ratio of 19.97, a price-to-earnings-growth ratio of 3.19 and a beta of 1.15. The company has a quick ratio of 0.83, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. The company’s 50 day moving average is $86.31 and its 200-day moving average is $86.14. GE HealthCare Technologies Inc. has a 12-month low of $74.51 and a 12-month high of $94.80.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its earnings results on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.19. The business had revenue of $5.32 billion for the quarter, compared to analysts’ expectations of $5.33 billion. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. Sell-side analysts predict that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current year.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.